The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials

LCZ696 is a novel neuroendocrine inhibitor that has been widely used in heart failure (HF). However, its advantage over other neuroendocrine inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin-receptor blockers (ARBs) has not been fully elucidated. This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, He, Qian, Mo, Dun-Chang, Chen, Long, Lu, Jia-Lu, Li, Rui-Xing, Huang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
3400 Cardiovascular
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575833/
https://www.ncbi.nlm.nih.gov/pubmed/36254034
http://dx.doi.org/10.1097/MD.0000000000030904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575833/
https://www.ncbi.nlm.nih.gov/pubmed/36254034
http://dx.doi.org/10.1097/MD.0000000000030904

Ejemplares similares